OTCMKTS:MATN Mateon Therapeutics (MATN) Stock Price, News & Analysis $0.10 +0.00 (+4.17%) As of 10/15/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Mateon Therapeutics Stock (OTCMKTS:MATN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mateon Therapeutics alerts:Sign Up Key Stats Today's Range$0.10▼$0.1050-Day Range$0.04▼$0.1052-Week Range$0.13▼$0.38Volume264,003 shsAverage Volume338,444 shsMarket Capitalization$9.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mateon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies that selectively target tumor tissue. The company’s platform leverages tumor-activated peptides designed to bind to the fibrin–fibronectin complexes uniquely present in solid tumors, with the goal of improving the therapeutic index of cytotoxic payloads while limiting off-target effects. Its lead asset, MH1, is a peptide–drug conjugate in Phase I clinical trials for advanced solid tumors. MH1 is engineered to remain inert in circulation and to be activated by tumor-associated proteases, delivering potent chemotherapeutic agents directly to the tumor microenvironment. Mateon also maintains a preclinical pipeline exploring additional peptide constructs intended to address cancers with high unmet medical need, such as ovarian and colorectal indications. Headquartered in Redwood City, California, Mateon collaborates with academic research centers and contract development organizations to advance its candidates through IND-enabling studies and early-stage clinical work. The company’s leadership team combines experience in oncology drug development, peptide chemistry and clinical operations, positioning Mateon to progress its targeted therapies toward regulatory milestones and potential strategic partnerships.AI Generated. May Contain Errors. Read More Receive MATN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mateon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MATN Stock News HeadlinesMateon Therapeutics (OTCMKTS:MATN) Stock Passes Above 200-Day Moving Average - What's Next?October 16 at 2:58 AM | americanbankingnews.comViking Therapeutics Inc.February 27, 2024 | wsj.com"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy… it's the starting gun for what I'm calling the "Great Crypto Revolution."October 16 at 2:00 AM | Crypto 101 Media (Ad)Sorrento Therapeutics Stock (OTC:SRNEQ), Quotes and News SummaryFebruary 25, 2023 | benzinga.comSee More Headlines MATN Stock Analysis - Frequently Asked Questions How have MATN shares performed this year? Mateon Therapeutics' stock was trading at $0.0350 at the beginning of the year. Since then, MATN stock has increased by 185.7% and is now trading at $0.10. How were Mateon Therapeutics' earnings last quarter? Mateon Therapeutics, Inc. (OTCMKTS:MATN) announced its quarterly earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). How do I buy shares of Mateon Therapeutics? Shares of MATN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mateon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mateon Therapeutics investors own include Amarin (AMRN), Cyclacel Pharmaceuticals (CYCC), Catalyst Pharmaceuticals (CPRX), Oramed Pharmaceuticals (ORMP), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP) and BioLineRx (BLRX). Company Calendar Last Earnings5/15/2019Today10/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:MATN Previous SymbolNASDAQ:MATN CIK908259 Webwww.mateon.com Phone650-635-7000FaxN/AEmployees13Year Founded1996Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-64.66% Return on Assets-42.92% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book0.50Miscellaneous Outstanding Shares90,240,000Free FloatN/AMarket Cap$9.02 million OptionableNot Optionable Beta1.33 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:MATN) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWall St’s “AI Godfather” breaks his silenceWhats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThis dark force is about to change everythingTwo Nobel Prize winners warn of this once-in-a-generation wealth shift…THE FINAL DISPLACEMENT An unstoppabl...Porter & Company | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mateon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mateon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.